ALEC News

Alector to Participate in Upcoming Healthcare Conferences

ALEC

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $10

ALEC

May 9, 2025
Read more →

Alector Q1 EPS $(0.41) Beats $(0.48) Estimate, Sales $3.67M Miss $4.38M Estimate

ALEC

May 8, 2025
Read more →

12 Health Care Stocks Moving In Friday's Pre-Market Session

ALEC

April 25, 2025
Read more →

12 Health Care Stocks Moving In Thursday's After-Market Session

ALEC

April 24, 2025
Read more →

Alector Completes Enrollment In PROGRESS-AD Phase 2 Clinical Trial If AL101/GSK4527226 For Individuals With Early Alzheimer's Disease

ALEC

April 17, 2025
Read more →

Morgan Stanley Assumes Alector at Underweight, Lowers Price Target of $1.5

ALEC

March 7, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Alector, Maintains $7 Price Target

ALEC

February 27, 2025
Read more →

Alector Sees FY2025 collaboration revenue to be between $5 million and $15 million

ALEC

February 26, 2025
Read more →

Alector Q4 2024 GAAP EPS $(0.02) Up From $(0.49) YoY, Sales $54.240M Beat $16.621M Estimate

ALEC

February 26, 2025
Read more →

Alector Highlights Strategic Focus For 2025, Phase 3 INFRONT-3 Data On Latozinemab For FTD-GRN By Q4 2025; 75% Enrollment For AL101 Trial In Early Alzheimer's Achieved; $457.2M Cash Expected To Fund Operations Through 2026

ALEC

January 13, 2025
Read more →

Alector Q3 EPS $(0.43) Beats $(0.53) Estimate, Sales $15.34M Miss $15.70M Estimate

ALEC

November 6, 2024
Read more →

Alector Initiates Phase 1 Clinical Trial Of AL044 For The Treatment Of Alzheimer's Disease

ALEC

September 12, 2022
Read more →

Dow Climbs More Than 400 Points, S&P 500 Rises 1.5%

ALEC

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday.

September 9, 2022
Read more →

Morgan Stanley Downgrades Alector: Here's What You Need To Know

ALEC

Morgan Stanley downgraded its rating of Alector (NASDAQ:ALEC) to Equal-Weight with a price target of $13.00, changing its price target from $27.00 to $13.00. Shares of Alector are trading down 12.47% over the last 24 hours, at $9.62 per share.

September 9, 2022
Read more →

Nasdaq Jumps Over 200 Points, Crude Oil Rises Sharply

ALEC

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.

September 9, 2022
Read more →

Enphase Energy, Immunocore And Some Other Big Stocks Moving Lower On Friday

ALEC

U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Friday. Here are some big stocks recording gains in today’s session.

September 9, 2022
Read more →

Morgan Stanley Downgrades Alector to Equal-Weight, Lowers Price Target to $13

ALEC

September 9, 2022
Read more →